Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the three and nine months ended September 30, 2018.

Recent Corporate Highlights

• Raised gross proceeds of $41.9 million in equity funding through October 10, 2018. After deducting the underwriter discount, placement agent fees, and other offering expenses the Company received net proceeds of approximately $37 million. 
• Announced additional positive data from its Phase 2a clinical study of its NasoVAX intranasal influenza vaccine candidate.  The new data showed that serum antibody levels for NasoVAX were stable over a six-month time period when compared to Fluzone’s antibody levels, which declined by over 50% during the same time period. Additionally, a significant mucosal immune response was observed one month after vaccination when compared to both placebo and Fluzone®.  As in the prior clinical studies, NasoVAX again had a clean safety profile.  The Company previously announced positive results from the study in 60 healthy individuals, which demonstrated NasoVAX to be well-tolerated at all doses and showed 100% seroprotection at the two highest dose levels.  Additionally, NasoVAX demonstrated the ability to elicit a significant T cell immune response as compared to Fluzone.  These new data identify another potentially important type of immunity induced by NasoVAX and indicate that NasoVAX may have a higher likelihood of protection throughout the entire flu season. 
• Received an award of $2.5 million in additional BARDA funding to support NasoShield development.  The funding is intended to allow vaccine characterization including key formulation parameters and batch consistency.  Additionally, Altimmune will assay clinical samples from its ongoing Phase 1 clinical trial for mucosal immune response and compare different methods of administration in preclinical models. 
• Announced initial single-dose data from its Phase 1 study of NasoShield, an anthrax vaccine candidate.  This portion of the ongoing study assessed the safety and immunogenicity of a single intranasal dose of NasoShield in four dose cohort levels and showed NasoShield to be safe and well-tolerated with no serious adverse events. The immunogenicity data suggest that NasoShield may require more than one dose for a robust immune response.  The program is funded through a contract with the Biomedical Advanced Research and Development Authority (“BARDA”) which runs through September 2021 and, if all options are exercised, is expected to provide funding through the end of Phase 2 development. Immunogenicity data for the two-dose cohort will be available in the fourth quarter of 2018.

“The proceeds provided by our recent financings will allow us to invest significantly in the development of NasoVAX and to support our Company going forward,” said William J. Enright, Chief Executive Officer of Altimmune. “Our developing pipeline and novel approaches to vaccines are quite differentiated from other approaches making these large markets attractive opportunities for Altimmune.”

Third Quarter 2018 Financial Highlights

• During the quarter the Company received $4.3 million of net proceeds from a registered direct offering which brought September 30, 2018 cash on hand to approximately $8.0 million. 
• Subsequent to quarter end, the Company received additional net proceeds of approximately $32.7 million related to its October 2 Underwritten Public Offering and October 10 Registered Direct Offering. 
• Third quarter revenue was $2.6 million compared to $4.6 million in the prior year period.  Revenue fluctuated in proportion to our research and development expenses for the NasoShield and SparVax-L programs. 
• Research and development expenses were $4.7 million compared to $5.9 million in the prior year period.  The decrease is primarily attributable to lower spending on NasoShield manufacturing when compared to the same period in 2017. 
• General and administrative expenses were $2.0 million as compared with $3.0 million for the same period in 2017.  The decrease is primarily attributable to 2017 professional services related to the integration of the newly merged entity that did not recur in 2018.  
• Other Income (expense) was $0.9 million compared to ($0.5) million for the same period in 2017.  The change was primarily due to the release of warrant liability associated with warrant exchanges consummated during the quarter. 
• Net loss attributed to common stockholders was $2.3 million compared to $31.9 million for the same period in 2017.  The increase was due primarily to $26.6 million goodwill impairment in 2017 in addition to the activity described above.

About AltimmuneAltimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.

Forward-Looking Statement Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: the terms of the Company’s Series B preferred stock offering and related warrants; our lack of financial resources and access to capital; realizing the benefits of the merger between Altimmune, Inc. and PharmAthene, Inc.; our ability to utilize the benefits of our tax assets and the results of a tax examination initiated by the IRS; clinical trials and the commercialization of proposed product candidates (such as marketing, regulatory, product liability, supply, competition, dependence on third parties and other risks); the regulatory approval process; dependence on intellectual property; the Company’s BARDA contract and other government programs, reimbursement and regulation. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, which are available at www.sec.gov.

ContactsBill Enright                                                                             President and CEO                                                                  Phone: [phone]                                                              

Ashley R. RobinsonManaging Director LifeSci AdvisorsPhone: 617-535-7742

ALTIMMUNE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
		Three Months Ended September 30,								Nine Months Ended September 30,
		2018				2017				2018				2017
Revenue
Research grants and contracts		$	2,629,446			$	4,565,251			$	7,727,681			$	7,892,919
License revenue			4,947				26,689				14,833				36,565
Total revenue			2,634,393				4,591,940				7,742,514				7,929,484
Operating expenses
Research and development			4,728,726				5,905,552				15,394,616				13,946,403
General and administrative			1,963,733				3,038,756				7,345,651				6,863,782
Goodwill impairment charges			—				26,600,000				490,676				26,600,000
Total operating expenses			6,692,459				35,544,308				23,230,943				47,410,185
Loss from operations			(4,058,066	)			(30,952,368	)			(15,488,429	)			(39,480,701	)
Other income (expense):
Changes in fair value of warrant liability, including gain (loss) on exchange			806,224				(508,316	)			(2,874,484	)			(508,316	)
Changes in fair value of embedded derivatives			185,768				(1,157	)			183,638				(1,157	)
Interest expense			(166,946	)			(2,344	)			(169,737	)			(160,103	)
Interest income			21,100				15,372				78,306				19,538
Other income (expense)			31,378				10786				289,053				9,839
Total other income (expense)			877,524				(485,659	)			(2,493,224	)			(640,199	)
Net loss before income tax benefit			(3,180,542	)			(31,438,027	)			(17,981,653	)			(40,120,900	)
Income tax benefit			829,393				1,532,790				3,318,124				2,526,499
Net loss			(2,351,149	)			(29,905,237	)			(14,663,529	)			(37,594,401	)
Other comprehensive income (loss) – foreign currency translation adjustments			—				(1,028,033	)			(463,177	)			(2,864,839	)
Comprehensive loss		$	(2,351,149	)		$	(30,933,270	)		$	(15,126,706	)		$	(40,459,240	)
Net loss		$	(2,351,149	)		$	(29,905,237	)		$	(14,663,529	)		$	(37,594,401	)
Preferred stock accretion, contributions, and dividends			64,139				(1,962,072	)			(2,527,275	)			(2,125,141	)
Net loss attributed to common stockholders		$	(2,287,010	)		$	(31,867,309	)		$	(17,190,804	)		$	(39,719,542	)
Weighted-average common shares outstanding, basic and diluted			1,321,289				517,596				983,651				386,524
Net loss per share attributed to common stockholders, basic and diluted		$	(1.73	)		$	(61.57	)		$	(17.48	)		$	(102.76	)

ALTIMMUNE, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
		September 30,				December 31,
		2018				2017
ASSETS
Current assets:
Cash and cash equivalents		$	7,964,002			$	8,769,465
Restricted cash			34,174				3,534,174
Total cash, cash equivalents and restricted cash			7,998,176				12,303,639
Accounts receivable			2,547,402				3,806,239
Tax refund receivable			976,523				6,361,657
Prepaid expenses and other current assets			443,929				994,332
Total current assets			11,966,030				23,465,867
Property and equipment, net			1,407,080				603,146
Intangible assets, net			38,339,086				38,722,270
Other assets			1,149,185				238,917
Total assets		$	52,861,381			$	63,030,200
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY
Current liabilities:
Notes payable		$	1,467,260			$	49,702
Accounts payable			150,738				129,075
Accrued expenses and other current liabilities			6,532,924				3,625,257
Current portion of deferred revenue			19,753				19,753
Current portion of deferred rent			173,952				15,914
Total current liabilities			8,344,627				3,839,701
Deferred income taxes			2,891,634				5,938,402
Other long-term liabilities			1,941,932				4,574,507
Total liabilities			13,178,193				14,352,610
Contingencies (Note 16)
Series B redeemable convertible preferred stock; $0.0001 par value; 16,000 shares designated; 0 and 12,177 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively.			—				9,281,767
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 and 100,000,000 shares authorized; 1,726,198 and 609,280 shares issued; 1,725,630 and 608,499 shares outstanding at September 30, 2018 and December 31, 2017, respectively			173				61
Additional paid-in capital			137,071,546				121,657,587
Accumulated deficit			(92,348,368	)			(77,684,839	)
Accumulated other comprehensive loss – foreign currency translation adjustments			(5,040,163	)			(4,576,986	)
Total stockholders’ equity			39,683,188				39,395,823
Total liabilities and stockholders’ equity		$	52,861,381			$	63,030,200